Consensus Clene Inc.

Equities

CLNN

US1856341029

Market Closed - Nasdaq Other stock markets 21:00:00 01/05/2024 BST			5-day change	1st Jan Change
0.437 ^USD	+1.20%		+29.67%	+47.34%

04-16	Clene Inc. and Clene Nanomedicine, Inc. Presented the Phase 2 VISIONARY-MS Long term Extension Study Results at the 2024 American Academy of Neurology Annual Meeting in Denver	CI
03-15	Clene Inc. Announces Peer-Reviewed Publication Characterizing the Protein Corona of the Investigational Neurodegenerative Disease Drug, CNM-Au8	CI

Evolution of the average Target Price on Clene Inc.

Price target over the last 5 years

History of analyst recommendation changes

baff4016eeea6c4.bkPdxKGGeTreHEtCsR4hdd-64fLxhOW1ThLUvoVYmkU.HG638vG2Jn6RQw82yWYUALDzmZ23sa7PBEu-ycIv3BAse5CmxLQyCJ9lHg~6029f377da2d41399b9e6d0d773a25bc

Analyst Recommendations on Clene Inc.

Benchmark Cuts Price Target on Clene to $5 From $7, Maintains Buy Rating	30/06/23	MT
HC Wainwright Cuts Price Target on Clene to $7 From $15, Keeps Buy Rating	21/06/23	MT
EF Hutton Adjusts Clene Price Target to $10 From $13, Maintains Buy Rating	20/06/23	MT
Cantor Fitzgerald Adjusts Price Target on Clene to $4 From $5, Maintains Overweight Rating	16/05/23	MT
Benchmark Adjusts Price Target on Clene to $7 From $11, Keeps Buy Rating	10/04/23	MT
Cantor Fitzgerald Adjusts Price Target on Clene to $8 From $6, Maintains Buy Rating	10/03/23	MT
EF Hutton Starts Clene at Buy With $13 Price Target	08/03/23	MT
Oppenheimer Downgrades Clene to Perform From Outperform, Removes $17 Price Target	04/10/22	MT
Canaccord Genuity Adjusts Clene's Price Target to $6 From $10, Reiterates Buy Rating	04/10/22	MT
Benchmark Adjusts Clene's Price Target to $11 From $25, Reiterates Buy Rating	04/10/22	MT
Oppenheimer Adjusts Clene's Price Target to $17 From $16, Maintains Outperform Rating	17/08/22	MT
Cantor Fitzgerald Adjusts Clene Price Target to $12 From $10, Maintains Overweight Rating	16/08/22	MT
HC Wainwright Initiates Clene at Buy With $16 Price Target	18/07/22	MT
Clene Reports Decreased Mortality Rates in RESCUE-ALS Trial	14/07/22	MT
Canaccord Genuity Starts Clene at Buy With $10 Price Target	02/05/22	MT
Oppenheimer Adjusts Clene's Price Target to $19 From $20, Maintains Outperform Rating	15/02/22	MT
Cantor Fitzgerald Adjusts Clene's Price Target to $15 From $24, Reiterates Overweight Rating	03/11/21	MT
CLENE : Oppenheimer Initiates Coverage on Clene With Outperform Rating, $20 Price Target	28/09/21	MT
CLENE : Maxim Group Starts Clene at Buy With $18 Price Target	20/05/21	MT
CLENE : Cantor Fitzgerald Starts Clene at Overweight With $22 Price Target	03/05/21	MT
CLENE : Benchmark Starts Clene at Buy With $25 Price Target	02/03/21	MT
CLENE : Roth Capital Starts Clene at Buy with $24 Price Target	03/02/21	MT